ArticleWorld journal of surgical oncology2026
Abnormal expression of miR-22-5p in breast cancer patients and its correlation with 18 F-FDG PET/CT features and serum-related tumor markers.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the abnormal expression of miR-22-5p in the serum of breast cancer (BC) patients and its clinical significance, and to clarify the potential mechanism of action.
methodsA total of 130 female breast cancer patients diagnosed by 18 F-FDG PET-CT and surgical pathology, along with 130 healthy female controls, were enrolled. Real-time quantitative polymerase chain reaction was used to detect serum miR-22-5p expression. Receiver Operating Characteristic curve analysis was applied to evaluate the diagnostic potential of miR-22-5p in BC. A dual-luciferase reporter gene assay was performed to validate the targeting of the MAS1 gene by miR-22-5p.
resultsSerum miR-22-5p expression was significantly higher in BC patients than in healthy controls, and positively correlated with clinical stages (III/IV vs. I/II, p < 0.001). ROC curve analysis showed an AUC of 0.887 for diagnostic efficacy. miR-22-5p expression exhibited positive correlations with PET/CT metabolic parameters and serum tumor markers. Cell-based experiments confirmed that miR-22-5p directly targeted the 3’-UTR of the MAS1 gene, suppressing MAS1 mRNA expression. Knockdown of miR-22-5p inhibited the proliferation, migration, and invasion of BC cells, whereas concurrent suppression of MAS1 reversed these inhibitory effects.
conclusionsSerum miR-22-5p emerges as a potential biomarker for BC diagnosis, participating in tumor metabolism and progression by regulating the MAS1 gene. This finding provides a novel therapeutic direction for BC targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.